Status:

NOT_YET_RECRUITING

Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Lead Sponsor:

University Hospital Southampton NHS Foundation Trust

Collaborating Sponsors:

NIHR Southampton Respiratory Biomedical Research Centre

Asthma, Allergy and Inflammation Research (AAIR) Charity

Conditions:

Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease

Eligibility:

All Genders

28-85 years

Phase:

NA

Brief Summary

Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients. In previous research the investigators identified...

Detailed Description

Idiopathic pulmonary fibrosis (IPF) is the prototypic chronic progressive fibrotic interstitial lung disease (ILD). Progressive disease is characterised by breathlessness and exercise limitation and t...

Eligibility Criteria

Inclusion

  • Cases Inclusion Criteria
  • Patients aged 18-85 years with a prior specialist multidisciplinary team diagnosis of idiopathic pulmonary fibrosis (IPF) based on current established consensus guidelines.
  • Medical Research Council (MRC) breathlessness grade 1-3
  • Judged clinically stable for 3 months prior to recruitment by the investigator.
  • Exclusion Criteria
  • Baseline spirometry with FEV1/FVC ratio \< 0.7.
  • Neoplastic disease undergoing treatment or active follow up.
  • Presence of infection or exacerbation requiring hospitalization, within last 3 months.
  • Current tobacco smoker or use of nicotine containing vapes (within 3months)
  • Current use of ambulatory or long-term oxygen therapy (LTOT).
  • Peripheral oxygen saturations \<85% during 6-minute walk-test.
  • Any condition which would prevent completion of cycle-ergometer testing, pulmonary function testing (PFT) or 6-minute walk testing as judged by the investigator.
  • Participation in a pulmonary rehabilitation (PR) program in the last 3 months.
  • Any condition excluding CPET based on the absolute contraindication as the ACCP/ATS guidelines 2003
  • Positive pregnancy test in females of childbearing age.
  • Symptomatic peripheral vascular disease
  • Controls Control Inclusion Criteria
  • 1\) Age and sex-matched to participants in the IPF cohort Control Exclusion Criteria
  • Inability to give informed written consent
  • Malignancy (except localized squamous or basal cell skin carcinoma) undergoing active investigation, treatment, or follow-up
  • Significant cardiorespiratory disease as judged by the investigator
  • Diabetes mellitus requiring treatment with pharmacology therapy
  • Current tobacco smoker or use of nicotine containing vapes (within 3months)
  • Symptomatic peripheral vascular disease

Exclusion

    Key Trial Info

    Start Date :

    September 1 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    September 1 2026

    Estimated Enrollment :

    16 Patients enrolled

    Trial Details

    Trial ID

    NCT06488638

    Start Date

    September 1 2024

    End Date

    September 1 2026

    Last Update

    July 5 2024

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.